AIMC Topic: tau Proteins

Clear Filters Showing 31 to 38 of 38 articles

The Rational Discovery of a Tau Aggregation Inhibitor.

Biochemistry
Intrinsically disordered proteins play vital roles in biology, and their dysfunction contributes to many major disease states. These proteins remain challenging targets for rational ligand discovery or drug design because they are highly dynamic and ...

AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure.

NeuroImage
Utilizing [18F]-AV-1451 tau positron emission tomography (PET) as an Alzheimer disease (AD) biomarker will require identification of brain regions that are most important in detecting elevated tau pathology in preclinical AD. Here, we utilized an uns...

CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.

Neurobiology of aging
Cerebrospinal fluid (CSF) concentrations of YKL-40 that serve as biomarker of neuroinflammation are known to be altered along the clinico-biological continuum of Alzheimer's disease (AD). The specific structural cerebral correlates of CSF YKL-40 were...

Predicting and preventing Alzheimer's disease.

Science (New York, N.Y.)
With all the advances in both the science of aging and artificial intelligence (AI), we are in a propitious position to accurately and precisely determine who is at high risk of developing Alzheimer's disease years before signs of even mild cognitive...

Machine learning prediction of tau-PET in Alzheimer's disease using plasma, MRI, and clinical data.

Alzheimer's & dementia : the journal of the Alzheimer's Association
INTRODUCTION: Tau positron emission tomography (PET) is a reliable neuroimaging technique for assessing regional load of tau pathology in the brain, but its routine clinical use is limited by cost and accessibility barriers.

A Study on Machine Learning Models in Detecting Cognitive Impairments in Alzheimer's Patients Using Cerebrospinal Fluid Biomarkers.

American journal of Alzheimer's disease and other dementias
Several research studies have demonstrated the potential use of cerebrospinal fluid biomarkers such as amyloid beta 1-42, T-tau, and P-tau, in early diagnosis of Alzheimer's disease stages. The levels of these biomarkers in conjunction with the demen...

Prognostic Power? Do the Plasma Biomarkers, Neurofilament Light and Phospho-Tau 181, Improve Prediction of Progression to Alzheimer's Disease Using a Machine Learning Approach in the ADNI Cohort?

Journal of Alzheimer's disease : JAD
With the advent of therapeutics with potential to slow Alzheimer's disease progression the necessity of understanding the diagnostic value of plasma biomarkers is critical, not only for understanding the etiology and progression of Alzheimer's diseas...

MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum.

Radiology
Background PET can be used for amyloid-tau-neurodegeneration (ATN) classification in Alzheimer disease, but incurs considerable cost and exposure to ionizing radiation. MRI currently has limited use in characterizing ATN status. Deep learning techniq...